Gland Pharma shares climbed over 4% in early trade on Wednesday after the company reported strong financial results for the first quarter of FY26. The pharmaceutical major delivered robust growth across revenue, margins, and bottom-line performance, boosting investor sentiment.
For the quarter ended June 2025, the company’s revenue from operations stood at ₹1,505.6 crore, marking a 7% year-on-year (YoY) increase compared to ₹1,401.7 crore in Q1 FY25. The rise in revenue was largely driven by a better product mix and continued operational expansion.
Gross profit surged 18% YoY to ₹984.5 crore, up from ₹837.5 crore a year ago. As a result, the gross margin improved significantly to 65%, versus 60% in the same quarter last year.
EBITDA for the quarter jumped 39% YoY to ₹367.8 crore, compared to ₹265.4 crore in Q1 FY25. The EBITDA margin expanded by 549 basis points to 24%. On an adjusted basis—which includes employee stock option-related costs—EBITDA came in even stronger at ₹373.7 crore, registering a 41% YoY growth. The adjusted EBITDA margin improved to 25%, up 589 basis points.
Profit before tax (PBT) rose 43% YoY to ₹312.7 crore, while net profit (PAT) saw a sharp 50% surge to ₹215.5 crore, as compared to ₹143.8 crore in the year-ago period. The PAT margin also improved by 405 basis points, reaching 14% from 10% last year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.